Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

PD-1 inhibitors

This page shows the latest PD-1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Gilead makes a play for novel cancer drug with Tizona deal

Gilead makes a play for novel cancer drug with Tizona deal

anti-PD-1/L1 therapies and deepen responses in tumours that are sensitive to these treatments. ... Gilead, however, is looking past PD-1/L1 inhibitors to the next class of transformative treatments, with its play for Tizona just the latest in a string of

Latest news

  • Tecentriq misses the mark in advanced ovarian cancer Tecentriq misses the mark in advanced ovarian cancer

    Tecentriq is part of a new class of immunotherapy treatments, also known as PD-1/L1 inhibitors, that have transformed the market over the last few years. ... The FDA approval for Imfinzi makes AZ’s drug the first PD-1/PD-L1 inhibitor to challenge

  • Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

    1/PD-L1 inhibitors spilling across a number of cancer types and ramping up the competition. ... However, Bavencio lagged behind Keytruda even in that indication, after Merck &Co’s PD-1 inhibitor beat it to the punch after winning approval in RCC a few

  • AstraZeneca’s Imfinzi fails first-line bladder cancer test AstraZeneca’s Imfinzi fails first-line bladder cancer test

    At the moment, Tecentriq’s only direct competitor in the frontline setting is Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab), which is also approved for first-line use in ... DANUBE’s outcome means that for now Imfinzi will still have to

  • Immutep spikes on trial of its LAG-3 drug with Keytruda Immutep spikes on trial of its LAG-3 drug with Keytruda

    The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population ... so “the results showing an almost 50% [response] across all patients

  • Merck CFO: we’re not only about Keytruda Merck CFO: we’re not only about Keytruda

    particularly the first-line therapy segment where it has broad use as a monotherapy and with chemo across squamous and non-squamous cancer types as well as low- and high ... Bristol-Myers is in particular they're looking at those individuals in whom

More from news
Approximately 1 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Combining PD-(L) 1 and CTLA-4 inhibitors – which work on different signalling pathways but both activate T-cells – has improved efficacy in some cancers like melanoma, but disappointed elsewhere. ... Among the plethora in the pipeline, Aurigene and

  • The good, the bad and the ugly The good, the bad and the ugly

    But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Pharma deals in July 2015 Pharma deals in July 2015

    During July Sanofi entered into a new collaboration with Regeneron to develop novel antibody cancer treatments based on programmed cell death protein 1 (PD-1) inhibitors. ... 7, 200. Regeneron / Sanofi. Licence  &collaboration. Immuno-oncology PD-1

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....

Quick links